NCT04782089

Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer

A Phase II, Open, Single-center Study of PD-1 Antibody and PARP Inhibitor as Consolidation Treatment for Patients With Extensive Stage Small Cell Lung Cancer Who Have Not Progressed After First-line Treatment

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: Qilu Hospital of Shandong University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase II, Open, Single-center Study of Camrelizumab and Fluzoparib as Consolidation Treatment for Patients With Extensive stage small cell lung cancer Who Have Not Progressed after first-line treatment

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors	Camrelizumab+Fluzoparib：Q3W, Administration until disease progression or intolerable

Timeline

• Start date: 2021-05-06
• Primary completion: 2023-05-01
• Completion: 2024-06-01
• First posted: 2021-03-04
• Last updated: 2021-03-04